DDInter1938 DDInter640
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vincristine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib